0001827090-25-000036
SEC filingRevenue grew 11% to $210.6M in H1 2025, driven by software (+20%) and services (+4%), with improved gross margins and operating profitability.
For the six months ended June 30, 2025, total revenue increased 11% to $210.6 million from $190.0 million in the prior-year period. Software revenue grew 20% to $93.1 million, benefiting from the acquisition of Chemaxon (completed October 1, 2024) which contributed $10.6 million, as well as organic growth from existing customers. Services revenue rose 4% to $117.5 million, driven by technology-enabled services. Gross margin improved to 61.0% from 58.4%, as cost of revenue grew only 4% versus revenue growth of 11%, aided by lower employee-related costs and stock-based compensation.
Operating income turned positive to $17.2 million compared to an operating loss of $10.3 million in the prior year. The improvement was driven by revenue growth and a $14.2 million decrease in general and administrative expenses, which included a $11.6 million favorable remeasurement of contingent consideration. Net income was $2.8 million versus a net loss of $17.3 million. Adjusted diluted EPS rose to $0.21 from $0.17.
Software segment revenue increased 20% YoY to $93.1 million, primarily due to the Chemaxon acquisition and strong demand from existing customers. Services segment revenue grew 4% to $117.5 million, with continued uptake in technology-enabled services. The mix shift toward software (44% of total revenue vs 41% prior year) contributed to margin expansion, as software carries higher margins.
Management expects to continue investing in scientific talent, sales and marketing, R&D (including AI integration), and potential acquisitions. The company initiated a $100 million stock repurchase program, repurchasing $25 million in Q2 2025. No specific quantitative guidance was provided, but the company believes existing liquidity (cash of $162.3 million and $100 million revolving credit facility) is sufficient for near-term needs. The Chemaxon acquisition is expected to continue contributing to software growth. Regulatory and macroeconomic factors, including potential FDA reforms, could impact demand.
As of June 30, 2025, Certara holds $162.3M in cash and cash equivalents, down from $179.2M at December 31, 2024, primarily due to share repurchases and contingent consideration payments. Total debt stands at $297.2M (net of $2.8M issuance costs), including $3.0M current portion. The term loan carries a floating rate hedged via interest rate swaps; the effective interest rate was 7.4% for H1 2025. Shareholders' equity is $1.07B, reflecting accumulated other comprehensive income gains from FX translation.
The company has operating lease commitments of $16.9M with a weighted-average remaining term of 5.8 years and a discount rate of 5.6%. Contingent consideration liabilities total $19.2M (down from $43.9M at year-end 2024), primarily from prior acquisitions, with $18.9M paid in H1 2025 (cash and stock). No material purchase commitments for supplies or capacity were disclosed.
In April 2025, the board authorized a $100M stock repurchase program; $25.3M was deployed to repurchase 1.8M shares in H1 2025, leaving $74.8M remaining. No dividends were declared. Debt repayment was $1.5M (mandatory quarterly principal payments). Capital expenditures totaled $12.7M, including $0.5M for property/equipment and $12.2M for capitalized software development costs (6.1% of revenue).
Certara operates as a single reporting segment. For Q2 2025, revenue was $104.6M (up 12% YoY), with net loss of $2.0M (vs. loss of $12.6M in Q2 2024). Geographic mix: Americas ($73.0M, 70%), EMEA ($23.4M, 22%), Asia Pacific ($8.2M, 8%). The CODM uses consolidated net income for performance assessment and resource allocation.
Operating cash flow of $35.2M significantly exceeded net income of $2.8M, reflecting strong non-cash adjustments: depreciation and amortization ($37.4M), equity-based compensation ($15.3M), and a $5.9M gain from fair value changes in contingent consideration. Working capital consumed $15.6M, driven by decreases in accounts payable and deferred revenues. Capex intensity (capex/CFO) stood at 36%, with total capital spending of $12.7M including $12.2M of capitalized software. Financing outflows of $44.7M were dominated by $25.0M in share repurchases and $13.2M in contingent consideration payments. The company's net cash position decreased by $16.9M, ending at $179.2M. The strong CFO growth and manageable capex support ongoing capital returns.